In Vivo Transduction by Intravenous Injection of a Lentiviral Vector Expressing Human ADA into Neonatal ADA Gene Knockout Mice: A Novel Form of Enzyme Replacement Therapy for ADA Deficiency
Open Access
- 30 June 2006
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 13 (6), 1110-1120
- https://doi.org/10.1016/j.ymthe.2006.02.013
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Long-term efficacy of enzyme replacement therapy for Adenosine deaminase (ADA)-deficient Severe Combined Immunodeficiency (SCID)Clinical Immunology, 2005
- Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative ConditioningScience, 2002
- Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined ImmunodeficiencyNew England Journal of Medicine, 1999
- T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonatesNature Medicine, 1998
- T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 YearsScience, 1995
- Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA − Immunodeficient PatientsScience, 1995
- Adenosine–deaminase–deficient mice die perinatally and exhibit liver–cell degeneration, atelectasis and small intestinal cell deathNature Genetics, 1995
- Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice.Proceedings of the National Academy of Sciences of the United States of America, 1995
- T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.JCI Insight, 1993
- Complete sequence and structure of the gene for human adenosine deaminaseBiochemistry, 1986